A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

NCT03499223 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus
Diabetic Retinopathy
Macular Edema

Interventions

DRUG: Ranibizumab 0.5mg
DRUG: THR-317 8mg
DRUG: Sham injection

Sponsor

Oxurion